Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cidara Therapeutics, Inc.CDTX · Entity 69639 | 10% owner | November 15, 2017 | November 16, 2017 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | 10% owner | May 24, 2021 | May 26, 2021 |
| MACROGENICS INCMGNX · Entity 6104 | 10% owner | October 02, 2023 | October 04, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cidara Therapeutics, Inc.
Report date November 15, 2017 · Filed November 16, 2017
Jointly reported with BIOTECH TARGET N V
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,295,272 |
Reported balance
After 2017-11-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-11-15 · Purchase · Acquired 60,000 · Balance 2,295,272 |
Esperion Therapeutics, Inc.
Report date May 24, 2021 · Filed May 26, 2021
Jointly reported with BIOTECH TARGET N V
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,477,964 |
Reported balance
After 2021-05-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-05-24 · Purchase · Acquired 100,000 · Balance 4,477,964 |
MACROGENICS INC
Report date October 02, 2023 · Filed October 04, 2023
Jointly reported with BIOTECH TARGET N V
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,929,963 |
Reported balance
After 2023-10-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-10-02 · Purchase · Acquired 150,000 · Balance 9,929,963 |
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Black Diamond Therapeutics, Inc.
Report date March 19, 2025 · Filed March 21, 2025
Jointly reported with BIOTECH GROWTH N V
Section 16 reporting ended · disclosed 2025-03-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,517,839 |
Reported balance
After 2025-03-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-03-19 · Sale · Disposed 1,000,000 · Balance 7,517,839 |
| Common StockSEC Table I · non-derivative | Direct | 7,217,839 |
Reported balance
After 2025-03-19 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-03-19 · Sale · Disposed 300,000 · Balance 7,217,839 |
| Common StockSEC Table I · non-derivative | Direct | 6,217,839 |
Reported balance
After 2025-03-19 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-03-19 · Sale · Disposed 1,000,000 · Balance 6,217,839 |
| Common StockSEC Table I · non-derivative | Direct | 4,217,839 |
Reported balance
After 2025-03-19 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2025-03-19 · Sale · Disposed 2,000,000 · Balance 4,217,839 |
| Common StockSEC Table I · non-derivative | Direct | 3,817,839 |
Reported balance
After 2025-03-19 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2025-03-19 · Sale · Disposed 400,000 · Balance 3,817,839 |
| Common StockSEC Table I · non-derivative | Direct | 3,233,547 |
Reported balance
After 2025-03-19 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2025-03-19 · Sale · Disposed 584,292 · Balance 3,233,547 |
| Common StockSEC Table I · non-derivative | Direct | 2,733,547 |
Reported balance
After 2025-03-19 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2025-03-19 · Sale · Disposed 500,000 · Balance 2,733,547 |
ESSA Pharma Inc.
Report date November 01, 2024 · Filed November 05, 2024
Jointly reported with BIOTECH GROWTH N V
Section 16 reporting ended · disclosed 2024-11-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 5,879,583 |
Reported balance
After 2024-11-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-11-01 · Sale · Disposed 2,000,000 · Balance 5,879,583 |
| Common SharesSEC Table I · non-derivative | Direct | 3,879,583 |
Reported balance
After 2024-11-01 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-11-01 · Sale · Disposed 2,000,000 · Balance 3,879,583 |
| Common SharesSEC Table I · non-derivative | Direct | 1,879,583 |
Reported balance
After 2024-11-01 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-11-01 · Sale · Disposed 2,000,000 · Balance 1,879,583 |
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-01 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2024-11-01 · Sale · Disposed 1,879,583 · Balance 0 |
Molecular Templates, Inc.
Report date November 14, 2024 · Filed November 19, 2024
Jointly reported with BIOTECH TARGET N V
Section 16 reporting ended · disclosed 2024-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-11-14 · Sale · Disposed 1,279,820 · Balance 0 |
| Prefunded Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 134,667 |
Reported balance
After 2024-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-02 · Purchase · Acquired 134,667 · Balance 134,667 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. |
| Common Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2029-04-02 | Direct | 769,334 |
Reported balance
After 2024-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-02 · Purchase · Acquired 769,334 · Balance 769,334 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.
Radius Health, Inc.
Report date August 15, 2022 · Filed August 30, 2022
Jointly reported with BIOTECH TARGET N V
Section 16 reporting ended · disclosed 2022-08-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-08-11 · Other · Disposed 8,733,538 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2025 Filed Mar 21, 2025 01:01 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 500,000 | $2.12 | $1,058,450.00 |
DisclosureSEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 7 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,733,547 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:01 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 584,292 | $1.95 | $1,141,239.13 |
DisclosureSEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 6 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,233,547 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:01 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 400,000 | $2.09 | $837,160.00 |
DisclosureSEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 5 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,817,839 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:01 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 2,000,000 | $2.00 | $4,000,800.00 |
DisclosureSEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 4 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,217,839 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:01 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,000,000 | $2.31 | $2,308,100.00 |
DisclosureSEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 3 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,217,839 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:01 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 300,000 | $1.94 | $582,900.00 |
DisclosureSEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,217,839 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:01 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,000,000 | $2.07 | $2,069,100.00 |
DisclosureSEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,517,839 Read SEC document |
| November 14, 2024 Filed Nov 19, 2024 02:12 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | SaleCommon Stock | 1,279,820 | $0.66 | $845,833.04 |
DisclosureSEC source: 0000950170-24-128208 · ownership.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 17:06 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | SaleCommon Shares | 1,879,583 | $1.51 | $2,843,809.08 |
DisclosureSEC source: 0000950170-24-121206 · ownership.xml · nonDerivative · entry 4 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 17:06 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | SaleCommon Shares | 2,000,000 | $1.53 | $3,058,800.00 |
DisclosureSEC source: 0000950170-24-121206 · ownership.xml · nonDerivative · entry 3 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,879,583 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 17:06 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | SaleCommon Shares | 2,000,000 | $1.53 | $3,051,800.00 |
DisclosureSEC source: 0000950170-24-121206 · ownership.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,879,583 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 17:06 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | SaleCommon Shares | 2,000,000 | $1.53 | $3,064,000.00 |
DisclosureSEC source: 0000950170-24-121206 · ownership.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,879,583 Read SEC document |
| April 02, 2024 Filed Apr 5, 2024 00:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Warrants (right to buy) · Derivative | 769,334 | $0.13 Strike: $2.35 | $96,166.75 |
DisclosureSEC source: 0000950170-24-042010 · ownership.xml · derivative · entry 3 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 769,334 Underlying: Common Stock · 769,334 shares Expires not disclosed F1 · derivative.exercise_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 19.99% of the number of the shares of Common Stock outstanding immediately following such exercise. F1 · derivative.expiration_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 19.99% of the number of the shares of Common Stock outstanding immediately following such exercise. Read SEC document |
| April 02, 2024 Filed Apr 5, 2024 00:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchasePrefunded Warrants (right to buy) · Derivative | 134,667 | $2.35 Strike: $0.00 | $316,332.78 |
DisclosureSEC source: 0000950170-24-042010 · ownership.xml · derivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,667 Underlying: Common Stock · 134,667 shares Expires 2029-04-02 F1 · derivative.exercise_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 19.99% of the number of the shares of Common Stock outstanding immediately following such exercise. F1 · derivative.expiration_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 19.99% of the number of the shares of Common Stock outstanding immediately following such exercise. Read SEC document |
| April 02, 2024 Filed Apr 5, 2024 00:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 250,000 | $2.35 | $587,500.00 |
DisclosureSEC source: 0000950170-24-042010 · ownership.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,279,820 Read SEC document |
| April 02, 2024 Filed Nov 19, 2024 02:12 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Warrants (right to buy) · Derivative | 769,334 | $0.13 Strike: $2.35 | $96,166.75 |
DisclosureSEC source: 0000950170-24-128208 · ownership.xml · derivative · entry 3 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 769,334 Underlying: Common Stock · 769,334 shares Expires 2029-04-02 F1 · derivative.exercise_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. F1 · derivative.expiration_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. Read SEC document |
| April 02, 2024 Filed Nov 19, 2024 02:12 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchasePrefunded Warrants (right to buy) · Derivative | 134,667 | $2.35 Strike: $0.00 | $316,332.78 |
DisclosureSEC source: 0000950170-24-128208 · ownership.xml · derivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,667 Underlying: Common Stock · 134,667 shares Expires not disclosed F1 · derivative.exercise_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. F1 · derivative.expiration_date: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 19:08 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 400,000 | $2.34 | $934,080.00 |
DisclosureSEC source: 0000950170-23-054142 · ownership.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,517,839 Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 19:31 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 150,000 | $4.46 | $669,585.00 |
DisclosureSEC source: 0000899243-23-019881 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,929,963 Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 19:39 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 200,000 | $5.26 | $1,052,840.00 |
DisclosureSEC source: 0000899243-23-018688 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,779,963 Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 19:14 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 4,255,319 | $0.47 | $1,999,999.93 |
DisclosureSEC source: 0000950170-23-033494 · ownership.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,447,322 Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 19:36 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 1,000,000 | $5.00 | $5,000,000.00 |
DisclosureSEC source: 0000950170-23-031386 · ownership.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,117,839 Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 17:37 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 1,740,000 | $5.49 | $9,555,036.00 |
DisclosureSEC source: 0000899243-23-016705 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,117,839 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 17:37 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 500,000 | $5.07 | $2,532,600.00 |
DisclosureSEC source: 0000899243-23-005209 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,579,963 Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:21 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 150,000 | $5.30 | $794,925.00 |
DisclosureSEC source: 0000899243-23-002378 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,079,963 Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 16:03 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 200,000 | $5.61 | $1,121,800.00 |
DisclosureSEC source: 0000899243-22-039423 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,929,963 Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 16:03 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 200,000 | $5.88 | $1,176,800.00 |
DisclosureSEC source: 0000899243-22-039423 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,729,963 Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 16:37 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 300,000 | $5.96 | $1,788,180.00 |
DisclosureSEC source: 0000899243-22-036996 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,529,963 Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 19:10 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 99,801 | $2.25 | $224,911.53 |
DisclosureSEC source: 0000899243-22-034751 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,377,839 Read SEC document |
| October 28, 2022 Filed Oct 31, 2022 19:20 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 172,974 | $2.18 | $376,962.24 |
DisclosureSEC source: 0000899243-22-034543 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,278,038 Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 18:57 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | PurchaseCommon Shares | 500,000 | $4.50 | $2,251,100.00 |
DisclosureSEC source: 0000899243-22-034401 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,879,583 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 19:20 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 191,678 | $1.87 | $359,223.74 |
DisclosureSEC source: 0000899243-22-034543 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,105,064 Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 18:57 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | PurchaseCommon Shares | 1,500,000 | $3.98 | $5,968,500.00 |
DisclosureSEC source: 0000899243-22-034401 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,379,583 Read SEC document |
| October 24, 2022 Filed Oct 25, 2022 20:19 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 250,000 | $4.36 | $1,090,500.00 |
DisclosureSEC source: 0000899243-22-034118 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,229,963 Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 20:24 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 87,850 | $1.51 | $132,750.14 |
DisclosureSEC source: 0000899243-22-034121 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,913,386 Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 20:19 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 250,000 | $4.63 | $1,157,100.00 |
DisclosureSEC source: 0000899243-22-034118 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,979,963 Read SEC document |
| October 20, 2022 Filed Oct 21, 2022 19:06 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 53,734 | $1.42 | $76,345.27 |
DisclosureSEC source: 0000899243-22-033945 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,825,536 Read SEC document |
| October 20, 2022 Filed Oct 21, 2022 19:03 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 285,977 | $4.00 | $1,143,564.83 |
DisclosureSEC source: 0000899243-22-033943 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,729,963 Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 19:06 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 77,689 | $1.32 | $102,774.78 |
DisclosureSEC source: 0000899243-22-033945 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,771,802 Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 19:03 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 168,422 | $3.70 | $623,919.30 |
DisclosureSEC source: 0000899243-22-033943 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,443,986 Read SEC document |
| August 11, 2022 Filed Aug 30, 2022 16:05 UTC | Radius Health, Inc. RDUS · Entity 124173 | OtherCommon Stock | 8,733,538 | $10.00 | $87,335,380.00 |
DisclosureSEC source: 0000899243-22-030031 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 19:21 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | PurchaseCommon Shares | 300,000 | $3.16 | $946,740.00 |
DisclosureSEC source: 0000899243-22-026410 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,879,583 Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 16:48 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | PurchaseCommon Shares | 241,665 | $3.13 | $756,798.11 |
DisclosureSEC source: 0000899243-22-026225 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,579,583 Read SEC document |
| July 14, 2022 Filed Jul 18, 2022 16:48 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | PurchaseCommon Shares | 347,204 | $2.79 | $969,428.29 |
DisclosureSEC source: 0000899243-22-026225 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,337,918 Read SEC document |
| May 18, 2022 Filed May 20, 2022 15:35 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 477,824 | $5.57 | $2,661,001.86 |
DisclosureSEC source: 0000899243-22-018984 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,733,538 Read SEC document |
| May 16, 2022 Filed May 18, 2022 16:21 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 200,000 | $1.18 | $236,200.00 |
DisclosureSEC source: 0000899243-22-018544 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,192,003 Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 14:50 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 255,711 | $2.57 | $657,867.69 |
DisclosureSEC source: 0000899243-22-016006 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,694,113 Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 16:28 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | SaleCommon Shares | 25,100 | $5.85 | $146,925.36 |
DisclosureSEC source: 0000899243-22-015831 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,990,714 Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 14:50 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 150,000 | $2.66 | $399,480.00 |
DisclosureSEC source: 0000899243-22-016006 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438,402 Read SEC document |
| April 19, 2022 Filed Apr 20, 2022 16:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 150,000 | $3.24 | $486,645.00 |
DisclosureSEC source: 0000899243-22-015145 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,288,402 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.